;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Mepolizumab: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mepolizumab (Bosatria) (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 9/22/2014
  • Mepolizumab: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mepolizumab (Bosatria) (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 9/22/2014
  • Nuedexta dextromethorphan/quinidine: Phase II data

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Product: Nuedexta dextromethorphan/quinidine (AVP-923) (formerly Neurodex) Business: Neurology Molecular target: NMDA receptor; Sigma-1 receptor Description…

    Published on 9/22/2014
  • NuQ test: Clinical trial data

    VolitionRx Ltd. (OTCBB:VNRX), Singapore Product: NuQ test Business: Diagnostic Molecular target: NA Description: Family of non-invasive blood tests for nucleosomes Indication: Detect colorectal cancer Endpoint: NA …

    Published on 9/22/2014
  • Odanacatib: Phase III data

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Odanacatib (formerly MK-0822) Business: Musculoskeletal Molecular target: Cathepsin K Description: …

    Published on 9/22/2014
  • Oleogel-S10: Phase III data

    Birken AG, Niefern-Oeschelbronn, Germany Product: Oleogel-S10 Business: Dermatology Molecular target: NA Description: Ointment containing dry extract from birch bark and sunflower oil Indication: Accelerate wound …

    Published on 9/22/2014
  • Ortho-ATI: Phase I data

    Orthocell Ltd. (ASX:OCC), Murdoch, Australia Product: Ortho-ATI Business: Musculoskeletal Molecular target: NA Description: Autologous tenocyte implantation Indication: Treat lateral epicondylitis Endpoint: Grip …

    Published on 9/22/2014
  • RPC1063: Additional Phase II data

    Receptos Inc. (NASDAQ:RCPT), San Diego, Calif. Product: RPC1063 Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Selective sphingosine-1-phosphate receptor 1 (…

    Published on 9/22/2014
  • Simtuzumab: Phase II data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Simtuzumab (GS-6624) (formerly AB0024) Business: Cancer Molecular target: Lysyl oxidase-like 2 (LOXL2) Description: Humanized mAb against lysyl oxidase-…

    Published on 9/22/2014
  • Sofosbuvir: Postmarketing study data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Sofosbuvir (Sovaldi) (GS-7977) (formerly PSI-7977) Business: Infectious Molecular target: HCV NS5B polymerase Description: Nucleotide analog HCV NS5B …

    Published on 9/22/2014
  • Xilonix: Interim Phase III data

    XBiotech Inc., Austin, Texas Product: Xilonix (MABp1) (CV-18C3, T2-18C3, RA-18C3, CA-18C3) Business: Endocrine/Metabolic Molecular target: Interleukin-1 (IL-1) alpha Description: Human mAb against IL-1 alpha Indication:…

    Published on 9/22/2014
  • Aironite: Phase II data

    Mast Therapeutics Inc. (NYSE-M:MSTX), San Diego, Calif. Product: Aironite (AIR001) Business: Cardiovascular Molecular target: NA Description: Inhaled nebulized sodium nitrite Indication: Treat pulmonary arterial …

    Published on 9/15/2014
  • Basimglurant: Development discontinued

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Basimglurant (RG7090, RO4917523) Business: Neurology Molecular target: Metabotropic glutamate receptor …

    Published on 9/15/2014
  • Benralizumab: Phase IIa data

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Benralizumab (KHK4563, MEDI-563) (formerly BIW-8405) Business: Pulmonary Molecular target: Interleukin-5 (…

    Published on 9/15/2014
  • BioChaperone Lispro U100: Preliminary Phase IIb data

    Adocia S.A. (Euronext:ADOC; Pink:ADOCY), Lyon, France Product: BioChaperone Lispro U100 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Ultra-fast acting formulation of insulin …

    Published on 9/15/2014
  • C16G2: Phase II data

    C3 Jian Inc., Marina del Rey, Calif. Product: C16G2 Business: Dental Molecular target: NA Description: Synthetic peptide targeting Streptococcus mutans derived from specifically targeted antimicrobial peptides (STAMPS) …

    Published on 9/15/2014
  • Cyramza ramucirumab: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab (LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) …

    Published on 9/15/2014
  • DLX105 topical: Phase II data

    Delenex Therapeutics AG, Zurich, Switzerland Product: DLx105 topical Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Topical formulation of an anti-tumor necrosis factor…

    Published on 9/15/2014
  • GNbAC1: Extension study data

    GeNeuro S.A., Geneva, Switzerland Product: GNbAC1 Business: Autoimmune Molecular target: NA Description: Humanized mAb targeting the envelop protein of human endogenous retrovirus type W (HERV-W) Indication: Treat …

    Published on 9/15/2014
  • IdeS: Phase II data

    Hansa Medical AB (SSE:HMED), Lund, Sweden Product: IdeS Business: Transplant Molecular target: NA Description: Streptococcus pyogenes enzyme that degrades IgG antibodies Indication: Prevent renal transplant rejection in…

    Published on 9/15/2014
  • Lyrica pregabalin: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lyrica pregabalin Business: Neurology Molecular target: GABA receptor Description: GABA receptor agonist Indication: Treat painful diabetic peripheral neuropathy (DPN) …

    Published on 9/15/2014
  • MIM-D3: Phase III data

    Mimetogen Pharmaceuticals Inc., Montral, Quebec Product: MIM-D3 Business: Ophthalmic Molecular target: Nerve growth factor (NGF) Description: Small molecule mimetic of nerve growth factor (NGF) Indication: Treat dry eye…

    Published on 9/15/2014
  • Moxifloxacin: Phase III data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Global Alliance for TB Drug Development, New York, N.Y. Product: Moxifloxacin (Actira, Octegra, Avalox) Business: Infectious Molecular target: DNA gyrase; Topoisomerase IV …

    Published on 9/15/2014
  • Prurisol abacavir acetate: Phase I data

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Prurisol abacavir acetate (KM-133) Business: Autoimmune Molecular target: NA Description: Small molecule ester of abacavir, a nucleoside analog reverse …

    Published on 9/15/2014
  • RPC1063: Phase II data

    Receptos Inc. (NASDAQ:RCPT), San Diego, Calif. Product: RPC1063 Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Selective sphingosine-1-phosphate receptor 1 (…

    Published on 9/15/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993